PMID: 15329598Aug 27, 2004Paper

Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate

Anesthesiology
Evan D KharaschChristine Hoffer

Abstract

Oral transmucosal fentanyl citrate (OTF) was developed to provide rapid analgesia and is specifically approved for treating breakthrough cancer pain. Fentanyl in OTF is absorbed across the oral mucosa, but a considerable portion is swallowed and absorbed enterally. Fentanyl metabolism is catalyzed by cytochrome P4503A4 (CYP3A). The role of intestinal or hepatic first-pass metabolism and CYP3A activity in OTF disposition is unknown. This investigation examined the influence of hepatic and intestinal CYP3A activity on the disposition and clinical effects of OTF. Healthy volunteers (n = 12) were studied in an Institutional Review Board-approved, randomized, balanced, four-way crossover. They received OTF (10 microg/kg) after hepatic/intestinal CYP3A induction by rifampin, hepatic/intestinal CYP3A inhibition by troleandomycin, selective intestinal CYP3A inhibition by grapefruit juice, or nothing (control). Plasma fentanyl and norfentanyl concentrations were determined by mass spectrometry. Fentanyl effects were measured by dark-adapted pupil diameter and subjective self-assessments using visual analog scales. : Peak plasma fentanyl concentrations, time to peak, and maximum pupil diameter change from baseline were unchanged after ri...Continue Reading

References

Aug 1, 1991·Anesthesiology·J B StreisandT H Stanley
Aug 1, 1987·Anesthesia and Analgesia·V N CirellaE J Pantuck
Jun 1, 1984·Clinical Pharmacology and Therapeutics·E Fuseau, L B Sheiner
Jul 1, 1980·Clinical Pharmacology and Therapeutics·D A McClain, C C Hug
May 1, 1996·Mayo Clinic Proceedings·K A Marshall
Oct 10, 1996·The New England Journal of Medicine·M H Levy
Nov 14, 1996·The New England Journal of Medicine·J A Levy
Aug 1, 1997·Clinical Pharmacokinetics·B Ameer, R A Weintraub
Jan 7, 1998·Anesthesiology·H Woehlck
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M ChristieR K Portenoy
May 21, 1999·Lancet·R K Portenoy, P Lesage
Jan 4, 2001·Drug Metabolism Reviews·S A WrightonP B Watkins
Aug 23, 2001·Journal of Pain and Symptom Management·R PayneR K Portenoy
Feb 22, 2002·Cancer·Sebastiano MercadanteUNKNOWN Steering Committee of the European Association for Palliative Care (EAPC) Research Network
Nov 5, 2002·Annual Review of Pharmacology and Toxicology·A G de BoerP J Gaillard
Nov 12, 2002·Clinical Pharmacology and Therapeutics·Ola DaleEvan D Kharasch
Mar 7, 2003·Clinical Pharmacology and Therapeutics·Evan D KharaschPamela Sheffels
May 2, 2003·The Journal of Pharmacology and Experimental Therapeutics·Jian Zong, Gary M Pollack
Jul 29, 2003·Clinical Pharmacokinetics·Mikko NiemiKari T Kivistö
Aug 9, 2003·Journal of Pain and Symptom Management·Ariel BergerGerry Oster
Sep 2, 2003·Pharmaceutical Research·Candace L Graff, Gary M Pollack
Nov 13, 2003·JAMA : the Journal of the American Medical Association·Eduardo Bruera, Hak Nam Kim
Nov 19, 2003·The Journal of Pain : Official Journal of the American Pain Society·Ewan McNicolUNKNOWN Americal Pain Society
Nov 19, 2003·The Journal of Pain : Official Journal of the American Pain Society·Barry V FortnerRussell K Portenoy
Dec 10, 2003·Clinical Pharmacology and Therapeutics·Evan D KharaschPam Sheffels
Feb 20, 2004·Journal of Clinical Pharmacology·Evan D KharaschDale Whittington

❮ Previous
Next ❯

Citations

Nov 8, 2007·European Journal of Clinical Pharmacology·Teijo I SaariKlaus T Olkkola
Aug 22, 2009·Journal of Palliative Medicine·Thomas B Strouse
Dec 22, 2010·Anesthesia and Analgesia·Evan D Kharasch
May 2, 2014·Journal of Pain and Symptom Management·Aleksandra Kotlinska-LemieszekPål Klepstad
Jan 25, 2011·Expert Opinion on Drug Metabolism & Toxicology·Michael J HanleyDavid J Greenblatt
Oct 16, 2014·Expert Opinion on Drug Metabolism & Toxicology·Rolf TeschkeAxel Eickhoff
Oct 2, 2012·Current Medical Research and Opinion·Nicholas MooreHélène Schneid
Oct 26, 2010·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Robert B Palmer
Feb 16, 2008·The American Journal of the Medical Sciences·Anne M BaciewiczTimothy H Self
Jan 13, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Ruimei YuanGuifang Xiang
Jul 28, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yi-Wei ChangTeng-Kuang Yeh
Jun 15, 2007·Annales Françaises D'anesthèsie Et De Rèanimation·M BinhasJ Marty
Feb 27, 2007·Journal of Clinical Pharmacology·Mona DarwishJohn G Jiang
Jan 25, 2006·Anaesthesia·B P Sweeney, J Bromilow
Feb 19, 2008·Journal of Forensic Sciences·Karen L WoodallBarry A McLellan
May 7, 2010·Journal of Veterinary Pharmacology and Therapeutics·B KuKanich, M Hubin
Jul 22, 2014·Journal of Forensic Sciences·Philip W MooreJoseph Ward Donovan
Jan 2, 2007·Journal of Pain and Symptom Management·Hiroaki MoriiAkira Yamaji
Apr 26, 2006·Best Practice & Research. Clinical Anaesthesiology·Bruno Guignard
Mar 20, 2012·Expert Opinion on Pharmacotherapy·Sebastiano Mercadante
Jul 7, 2012·Journal of Pain & Palliative Care Pharmacotherapy·Hideya KokubunKazuo Yago
Jun 5, 2013·Toxicology and Applied Pharmacology·Harish ShankaranJustin G Teeguarden
Jul 10, 2012·Journal of Pain and Symptom Management·Robert TwycrossAndrew Wilcock
Sep 19, 2015·Journal of Clinical Pharmacology·Sudeep R BistaStefanie Hennig
Oct 30, 2016·British Journal of Clinical Pharmacology·Evelien J M KuipCarin C D van der Rijt
May 8, 2018·European Journal of Hospital Pharmacy. Science and Practice·Robert JanknegtMorten Thronaes
Jun 22, 2018·Acta Anaesthesiologica Scandinavica·J LvY Wang
Feb 23, 2019·The Journal of Pharmacy and Pharmacology·Ala NozariJ A Jeevendra Martyn
Nov 28, 2017·Journal of Pain and Symptom Management·Harm WestdorpKris C P Vissers
Mar 23, 2021·Pharmacotherapy·Eric M KinneyBranden D Nemecek

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.